The Venture Codex Logo

The Venture Codex

Prime Capital

Level 26, 1 Bligh Street, Sydney, NSW, 2000, Australia

Overview

Prime Capital provides residential and commercial real estate mortgage brokerage loan operations.

Total investments
2
Lead investments
0
Investments · 12mo
1
Active investors
1

Sector focus

  • Mortgage
Visit website

Investment portfolio

  • Corgi

    Participated · Series B · May 2026

    Corgi is an AI-native, full-stack insurance carrier founded by Emily Yuan and Nico Laqua and headquartered in San Francisco. As a licensed carrier, it designs and manages insurance end-to-end and uses AI to power underwriting, policy management, and claims operations. The company launched its platform after receiving regulatory approval in July 2025 and initially focused on property-management insurance for startups. Corgi plans to expand its product suite into new verticals including trucking, payroll, and small-business insurance while broadening coverage and distribution. Financially, Corgi has raised over $268 million to date, including a $160 million Series B at a $1.3 billion valuation. The company is investing the new capital in AI systems, faster quoting, adaptive risk models, and operational scaling to support its growth plans.

  • Scivita Medical Technology

    Participated · Series B · Aug 2021

    Scivita Medical Technology Co., Ltd. is a Hong Kong-based medical device company that develops and manufactures endoscopy products, including 3D visualization systems, 4K camera systems, and multiple single-use videoscopes. The company offers a product range that includes 3D Visualization System, 4K UHD Camera System, 4K-3D Camera System, 4K Sinoscope, 4K Arthroscope, and single-use hystero, urology and broncho videoscopes. Scivita has established R&D centres in Suzhou, China and Tokyo, Japan to support simultaneous global R&D, patenting, registration and commercialization. The company intends to pursue simultaneous certification of related products in China, the United States, Japan, Europe and other regions and to expand global market penetration. Financially, Scivita completed a Series B financing of nearly RMB0.4 billion to support those efforts. The funds will be used for research and development, capacity expansion, and domestic and international commercialization of its endoscopy and related products.

Team

  • Marc Cummins

    Founder and Managing Partner

    LinkedIn